| Followers | 60 |
| Posts | 11415 |
| Boards Moderated | 0 |
| Alias Born | 01/31/2008 |
Friday, February 22, 2019 11:11:16 AM
The question is could Anavex have attracted an even better CEO for less money?
I seriously doubt it. Show me another small biotech CEO (under $1 billion market cap) who has:
1. Chemistry PhD to understand the science
2. Top business school Northwestern MBA to understand business strategy.
3. Previous CFO experience to understand company finance.
4. Wall Street investment banker small cap experience to understand how to fight off the short snakes and vipers.
5. A super ability to attract the best in the world to his scientific advisory board.
6. An unsurpassed ability to get others to finance our trials, thus minimizing dilution.
7. A visionary who is leading the effort to bring precision medicine to drug trials.
Most small biotech CEOS can't even tick 4 out of 7 of these boxes. Missling is 7 of 7.
You just have to look at the 4 clown CEOs in a row that ADXS has, to realize how blessed AVXL is to have Missling.
And he doesn't cost much in cash compensation, and most of his options have strike prices in the $6-8 range. So he won't make much until he drives the stock price up substantially.
I seriously doubt it. Show me another small biotech CEO (under $1 billion market cap) who has:
1. Chemistry PhD to understand the science
2. Top business school Northwestern MBA to understand business strategy.
3. Previous CFO experience to understand company finance.
4. Wall Street investment banker small cap experience to understand how to fight off the short snakes and vipers.
5. A super ability to attract the best in the world to his scientific advisory board.
6. An unsurpassed ability to get others to finance our trials, thus minimizing dilution.
7. A visionary who is leading the effort to bring precision medicine to drug trials.
Most small biotech CEOS can't even tick 4 out of 7 of these boxes. Missling is 7 of 7.
You just have to look at the 4 clown CEOs in a row that ADXS has, to realize how blessed AVXL is to have Missling.
And he doesn't cost much in cash compensation, and most of his options have strike prices in the $6-8 range. So he won't make much until he drives the stock price up substantially.
You have to ask yourself, "Do I feel lucky?" Well, do you short punk?
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
